Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ(株)【4598】の掲示板 2024/04/16〜2024/04/26

>>888

Cancers (Basel). 2023 Jun; 15(11): 2958. の総説によると、r/r AMLに対する競合薬はUproleselanくらいか？


他、r/r AML、Phase3, recruiting (NOT FLT3)で検索した結果：

・NCT05457361, in China：
VAH Versus VA for Salvage Therapy of R/R-AML

・NCT03765541, in France：
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia (DEXAML-03)

・NCT05726110, in China：
Selinexor in Combination With HAD or CAG Regimens in Relapsed or Refractory Acute Myeloid Leukemia

・NCT04722952, in China:
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML

・NCT05183035, in USA/Canada/Australia/New Zealand sites/LLS territory:
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

中国で実施された臨床試験結果で米国で承認得るのはハードルが高いかな。